Hiromi Nagano

Hiromi Nagano

Auto-generated profile, based on publicly available information

Hiromi Nagano

Department of Otolaryngology Head and Neck Surgery Kagoshima University Graduate School of Medical and Dental Sciences Kagoshima Japan

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 December 2017 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
HNHiromi Nagano
Hiromi Nagano
MKMasaki Kawabata
Masaki Kawabata
GSGen Sugita
Gen Sugita
ATAkitoshi Tsuruhara
Akitoshi Tsuruhara
JOJunichiro Ohori
Junichiro Ohori
KFKohtaro Fujihashi
Kohtaro Fujihashi

21 July 2022 in Molecular Imaging and Biology
Verified
Journal Article
Closed access
PDF file
MNMasatoyo Nakajo
Masatoyo Nakajo
KKKodai Kawaji
Kodai Kawaji
HNHiromi Nagano
Hiromi Nagano
MJMegumi Jinguji
Megumi Jinguji
AMAkie Mukai
Akie Mukai
Takashi YoshiuraTakashi Yoshiura
Takashi Yoshiura

7 March 2025 in Laryngoscope Investigative Otolaryngology
Verified
Journal Article
Open access
HNHiromi Nagano
Hiromi Nagano
HMHayato Matsumoto
Hayato Matsumoto
YAYumi Ando
Yumi Ando
MNMasatoyo Nakajo
Masatoyo Nakajo
MYMasaru Yamashita
Masaru Yamashita
Objectives: The purpose of this study is to investigate the genetic mutational status of anaplastic thyroid carcinoma (ATC) and its prognostic implications.Methods: Data were analyzed for 129 consecutive patients with ATC registered at the Japan National Cancer Center, Center for Cancer Genomics and Advanced Therapeutics (C‐CAT) between June 2019 and June 2024. Genetic alterations were determined by FoundationOne CDx or Liquid CDx next‐generation sequencing. The survival of patients was determined by the log‐rank test and a Cox proportional hazards model.Results: The top 30 mutations in ATC were TERT (98/129), TP53 (88/129), BRAF (72/129), CDKN2A (39/129), CDKN2B (29/129), LTK (26/129), NRAS (25/129), KMT2D (24/129), PIK3CA (26/129), NOTCH3 (27/129), NF2 (19/129), MTAP (17/129), TET2 (16/129), STK11 (15/129), ATM (14/129), FANCA (14/129), NF1 (13/129), DNMT3A (13/129), KIT (13/129), NOTCH1 (13/129), EP300 (12/129), BRCA2 (11/129), CARD11 (11/129), KEL (11/129), MSH3 (11/129), PTEN (11/129), RICTOR (11/129), TSC1 (11/129), ROS1 (10/129), and KMT2A (10/129) with 13.7 ± 0.5 (mean ± SEM) mutations/individual. Mutations in BRAF (p = 0.003), PIK3CA (p = 0.014), and BRCA2 (p = 0.036) were associated with a significantly better prognosis, whereas mutations in STK11 (p = 0.024) was associated with a significantly worse prognosis, as determined by log‐rank tests. The hazard ratios for cases with these mutations were 0.248 (95% CI, 0.0973–0.633, p = 3.5 × 10−3) for PIK3CA, 2.410 (1.054–5.515, p = 0.037) for STK11, and 0.157 (0.0376–0.659, p = 0.011) for BRCA2.Conclusions: In ATC, PIK3CA, and BRCA2 mutations were associated with a better prognosis, and STK11 mutation was associated with a poorer prognosis in this study.Level of Evidence: 3.

1 December 2021 in Auris Nasus Larynx
Verified
Journal Article
Closed access
HNHiromi Nagano
Hiromi Nagano
YFYoshinobu Fujiwara
Yoshinobu Fujiwara
HMHirohisa Matsuzaki
Hirohisa Matsuzaki
MUMizuo Umakoshi
Mizuo Umakoshi
JOJunichiro Ohori
Junichiro Ohori
YKYuichi Kurono
Yuichi Kurono


29 November 2017 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
KMKeiichi Miyashita
Keiichi Miyashita
JOJunichiro Ohori
Junichiro Ohori
HNHiromi Nagano
Hiromi Nagano
SFSatoshi Fukuyama
Satoshi Fukuyama
YKYuichi Kurono
Yuichi Kurono